Atea Pharmaceuticals - Our Science hero photo

RNA Viruses

The prevalent cause of severe human viral diseases.

Single-stranded positive-sense RNA viruses account for a large number of clinically serious global pathogens and are the cause of many potentially life-threatening diseases: coronaviruses, including SARS-CoV-2, the virus responsible for COVID-19, dengue, yellow fever, Ebola, Zika, West Nile, encephalitis viruses, hepatitis C, and RSV.

The activity of a key viral enzyme, RNA-dependent RNA polymerase, also known as RNA polymerase, is required for replication and propagation of these viruses. The structure of this enzyme is highly conserved across RNA viruses. Most viral RNA polymerases have been identified on the basis of comparative sequence analysis, but it is important to know that viral genome replication is initiated by two different and distinct mechanisms.

The use of nucleoside and nucleotide analogs to inhibit the viral RNA polymerase, thereby preventing propagation of the virus, is a well-documented and historically successful approach to treatment of various viral diseases, including HIV/AIDS, herpesvirus, hepatitis B and hepatitis C infections.

OUR PURINE NUCLEOTIDE PRODRUG PLATFORM

Uniquely active against RNA viruses.

We have produced a large library of nucleoside and nucleotide analogs prodrugs that specifically target viral RNA polymerases. Based on extensive knowledge and years of experience discovering and developing antivirals, our team of scientists has designed product candidates that include specific chemical modifications intended to enhance antiviral activity and maximize selectivity.

Unique prodrugs of nucleotide analogs are intrinsic to Atea’s innovative platform for developing orally administered, direct-acting antiviral therapies.

A graphic illustration of Atea’s different generations of phosphoramidates.

Atea’s Deep Antiviral Pipeline

Atea is advancing oral product candidates that are designed to be potent and selective, including nucleos(t)ide analogs being developed as either monotherapy or in combination with other antiviral agents. Each of the nucleos(t)ide analogs Atea is currently advancing in clinical development, specifically bemnifosbuvir (AT-527) and AT-752, have been derived from Atea’s proprietary nucleotide platform. These product candidates are designed to inhibit the enzymes central to viral replication while avoiding toxicity to host cells.

Pipelines & Programs

Atea is a clinical-stage biopharmaceutical company committed to addressing unmet medical needs through novel antiviral treatments.

Copyright © 2023 By Atea Pharmaceuticals. All Rights Reserved. Privacy Policy | Terms of Use